Pyridineamine compounds useful as Pim kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9802918-B2
Application number	US-201615353312-A
Country	US
Kind code	B2
Filing date	Nov 16, 2016
Priority date	May 29, 2015
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

First claim

What is claimed is:

1. A compound which is 4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]-N-{[6-(2,6-difluorophenyl)-5-fluoropyridin-2-yl]methyl}-6,7-dihydro-5H-cyclopenta[b]pyridin-3-amine, or a pharmaceutically acceptable salt thereof.

2. A composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

3. A method of inhibiting Pim1, Pim2, or Pim3 enzyme comprising contacting the enzyme with the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

4. A method of inhibiting Pim1 enzyme comprising contacting the enzyme with the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. A method of inhibiting Pim2 enzyme comprising contacting the enzyme with the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

6. A method of inhibiting Pim3 enzyme comprising contacting the enzyme with the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method of treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the cancer is a cancer wherein the expression or activity of at least one of Pim1, Pim2, and Pim3 is upregulated.

9. The method of claim 7 , wherein the cancer is a cancer wherein an oncogene is activated.

10. The method of claim 7 , wherein the cancer is a cancer wherein Myc or Bcl2 is activated.

11. The method of claim 7 , wherein the cancer is a solid tumor or a hematological cancer.

12. The method of claim 7 , wherein the cancer is prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancer of the head or neck, thyroid cancer, glioblastoma, sarcoma, bladder cancer, lymphoma, leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, diffuse large-B cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma or multiple myeloma.

13. A method of treating myeloproliferative disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the myeloproliferative disorder is polycythemia vera, essential thrombocythemia, chronic myelogenous leukemia, myelofibrosis, primary myelofibrosis, post polycythemia vera/essential thrombocythemia myelofibrosis, post-essential thrombocythemia myelofibrosis or post polycythemia vera myelofibrosis.

14. A method of treating an immune disorder comprising administering to a patient in need of such treatment a therapeutically effective amount of compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the immune disorder is multiple sclerosis, rheumatoid arthritis, allergy, food allergy, asthma, lupus, inflammatory bowel disease or ulcerative colitis, Crohn's disease, irritable bowel syndrome, pancreatitis, diverticulosis, Grave's disease, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, myasthenia gravis, vasculitis, autoimmune thyroiditis, dermatitis, psoriasis, scleroderma, systemic sclerosis, vitiligo, graft vs host disease, Sjogren's syndrome, glomerulonephritis or type I diabetes mellitis.

15. A method of treating atherosclerosis comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

16. A method of reducing angiogenesis or tumor metastasis, comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignees

• Incyte Corp

Inventors

• Vechorkin Oleg
• Li Yun-Long
• Zhuo Jincong

Classifications

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D401/14 Primary

  containing three or more hetero rings · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D409/14

  containing three or more hetero rings · CPC title